President Donald Trump’s nominee for FDA Commissioner, Martin A. Makary, MD, sought to assure senators that if confirmed, he would support efforts to expedite reviews of new drugs indicted for rare ...
The Florida surgeon general in January called for a halt in the use of covid mRNA vaccines. And in Texas, Attorney General ...
The list is part of Health Secretary Robert F. Kennedy Jr.'s push for "radical transparency." Experts say it could sow doubt ...
Stephen Krahling was a published cancer researcher when vaccine maker Merck brought him on board as a virologist in 1999. That’s when he says he found himself embroiled in an all-hands-on-deck ...
A longtime Johns Hopkins surgeon and best-selling author, he has advised the World Health Organization and been elected to ...
President Trump’s pick to lead the US Food and Drug Administration tells senators he will follow science and common sense ...
Analysts at Jefferies see Makary as a positive for the rare disease space, given his support for accelerated approvals and ...
Dr. Marty Makary, President Trump's pick to run the Food and Drug Administration, faced questions from the Senate HELP ...
Dr. Marty Makary is largely sidestepping Senate questions about his plans to lead the Food and Drug Administration.
Dr. Marty Makary, Trump's nominee for FDA Commissioner, breezed through his confirmation hearing despite tough questions from Democrats and Republicans.
AbbVie made a $350 million upfront payment to Gubra for rights to the drug, called GUB014295. Gubra is also eligible to receive another $1.9 billion if certain development and sales milestones are met ...
According to Halozyme, the new version of Keytruda infringes on its patents, the report said. USAID cuts put tuberculosis response in peril, WHO says The Trump administration's decision to pause U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback